Verein für
Association pour le
Associazione per il

medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2024 - 4

MQ, Universitätsspital Zürich, 8091 Zürich
Telefon 044 255 34 11, www.MQZH.ch, info@MQZH.ch

Survey Specimens
The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (http://www.uzl.usz.ch/).
The following survey specimens were produced specifically for MQ by a sub-contractor:
B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):
a Value known due to production.
b Certified reference value for use with special specimens
c Reference value determined by analysis
d Consensus values of expert laboratories
e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.
In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.
In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values
The standard uncertainty (u_x) is calculated using the following formula (ISO13528):
ux = (target value/100) * (1.25/square root of "number of participants") * %CV

- ux has the same unit as the target value
- ux can be compared with the standard deviation of the participants' collective (SD=target value*%CV/100)
- For participant numbers >18, the standard uncertainty (ux) is significantly lower than the scatter of the collective participants and can be neglected.

QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, ux, of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics

The results are shown graphically as follows:



Comparison of Devices
The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

.

Zürich, 8.12.2024

Dr. R. Fried
Survey Director

.

INR



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	16	100.0	0.0	0.0	1.56	3.9	e
2	Neoplastin R	15	100.0	0.0	0.0	1.66	4.7	e
3	Neoplastin Plus	9	100.0	0.0	0.0	2.00	6.2	e*
4	Recombiplastin 2G	15	100.0	0.0	0.0	1.68	5.9	e
5	Other methods	13	92.3	0.0	7.7	1.62	6.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Fibrinogen OA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	9	100.0	0.0	0.0	1.03	6.8	e*
2	Stago/STA	21	100.0	0.0	0.0	1.12	5.9	e
3	Fibrinogen Q.F.A.	16	93.7	0.0	6.3	1.08	7.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	6	100.0	0.0	0.0	37.8	7.1	e
2	Pathromtin SL	7	100.0	0.0	0.0	59.1	3.5	e
3	Stago/STA	23	100.0	0.0	0.0	50.9	5.4	e
4	aPTT-SP	11	100.0	0.0	0.0	40.4	5.6	e
5	Other methods	10	100.0	0.0	0.0	39.7	7.8	e

INR CoaguChek



QUALAB tolerance : 15 %

INR CoaguChek ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	910	98.4	0.9	0.7	2.9	4.1	e

Prothrombin time NT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	13	100.0	0.0	0.0	100	0.8	e
2	Neoplastin R	12	100.0	0.0	0.0	96	4.4	e
3	Neoplastin Plus	4	100.0	0.0	0.0	93	4.6	e*
4	STA-NeoPTimal	7	100.0	0.0	0.0	91	3.3	e
5	Recombiplastin 2G	11	100.0	0.0	0.0	99	3.7	e
6	Other methods	15	100.0	0.0	0.0	98	4.2	e

Fibrinogen N



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	11	90.9	9.1	0.0	2.67	7.3	e*
2	Stago/STA	19	100.0	0.0	0.0	2.98	5.2	e
3	Fibrinogen Q.F.A.	18	100.0	0.0	0.0	2.69	4.7	e
4	Fib Clauss (IL)	6	100.0	0.0	0.0	2.62	7.1	e*

Faktor V



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	94.0	7.3	e

aPTT N



QUALAB tolerance : 25 %

aPTT N (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	10	90.0	0.0	10.0	22.9	3.0	e
2	Pathromtin SL	7	100.0	0.0	0.0	39.1	7.4	e
3	Stago/STA	20	100.0	0.0	0.0	32.0	6.9	e
4	aPTT-SP	13	100.0	0.0	0.0	25.9	7.2	e
5	Other methods	6	100.0	0.0	0.0	36.2	1.7	e

Faktor VII



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	100.0	0.4	e

Prothrombin time HT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	14	100.0	0.0	0.0	98	4.0	e
2	Neoplastin R	14	100.0	0.0	0.0	94	5.6	e
3	Recombiplastin 2G	14	100.0	0.0	0.0	98	2.1	e
4	Other methods	9	100.0	0.0	0.0	100	2.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	12	83.4	8.3	8.3	0.10	14.5	a
2	ACL	21	100.0	0.0	0.0	0.24	13.6	a
3	Other methods	20	80.0	15.0	5.0	0.25	20.5	a

Fibrinogen H



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	3.12	6.2	e*
2	Stago/STA	16	100.0	0.0	0.0	3.17	5.2	e
3	Fibrinogen Q.F.A.	14	92.9	0.0	7.1	2.99	7.6	e*
4	Other methods	11	100.0	0.0	0.0	2.90	5.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	31.2	2.4	e
2	Actin FSL	6	83.3	0.0	16.7	33.3	4.8	e
3	Pathromtin SL	7	100.0	0.0	0.0	56.3	9.3	e*
4	Stago/STA	14	100.0	0.0	0.0	50.5	8.5	e
5	aPTT-SP	12	91.7	8.3	0.0	45.8	11.7	e*
6	Other methods	4	100.0	0.0	0.0	32.8	3.9	e

D-dimer



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche (Zitratplasma)	9	88.9	11.1	0.0	0.39	11.9	e*
2	STA Liatest	17	88.2	11.8	0.0	0.38	13.7	e*
3	Siemens Innovance	13	92.3	7.7	0.0	0.65	8.8	e
4	Pathfast	22	95.5	4.5	0.0	1.83	10.0	e
5	ACL	16	100.0	0.0	0.0	0.79	7.3	e
6	AQT 90 FLEX	5	100.0	0.0	0.0	0.27	5.5	e
7	VIDAS	16	100.0	0.0	0.0	0.53	7.7	a

5 additional results were submitted but not published because the method groups were too small. (< results per group)

D-Dimer Triage



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	209	84.2	10.5	5.3	202.42	13.0	e

D-dimer qn AFIAS



QUALAB tolerance : 21 %

D-dimer qn AFIAS (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	487	80.1	8.2	11.7	0.42	12.5	e

CoaguChek APTT



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	7	85.7	0.0	14.3	85.0	7.2	e

INR CCXS



QUALAB tolerance : 15 %

INR CCXS ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1318	99.2	0.3	0.5	2.8	3.7	e

INR HC



QUALAB tolerance : 15 %

INR HC ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemochron j.	5	100.0	0.0	0.0	5.2	6.2	e*

INR MI



QUALAB tolerance : 15 %

INR MI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	microINR Expert	15	60.0	13.3	26.7	2.0	11.6	e*
2	MicroINR	114	81.6	4.4	14.0	2.1	8.4	e

INR Xprecia



QUALAB tolerance : 15 %
(< 1.3: +/- 0.2)

INR Xprecia ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Xprecia	41	97.6	2.4	0.0	1.2	6.3	e

INR Lumira Dx



QUALAB tolerance : 15 %

INR Lumira Dx ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	7	100.0	0.0	0.0	1.3	7.0	e*

Anti-FXa (LMW-Heparin)



MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	13	84.6	15.4	0.0	0.64	13.7	e*
2	ACL	23	87.0	13.0	0.0	0.67	13.0	e*
3	Other methods	12	100.0	0.0	0.0	0.71	9.5	e*

Anti-FXa (Rivaroxaban)



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	12	91.7	8.3	0.0	71.12	11.6	e*
2	ACL	11	100.0	0.0	0.0	77.05	9.6	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Anti-FXa (Apixaban)



MQ tolerance : 20 %

Anti-FXa (Apixaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	8	100.0	0.0	0.0	283.50	8.5	e*
2	ACL	5	100.0	0.0	0.0	261.70	7.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Edoxaban)



MQ tolerance : 20 %

Anti-FXa (Edoxaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	105.00	11.8	e*

Anti-FIIa (Dabigatran)



MQ tolerance : 20 %

Anti-FIIa (Dabigatran) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	218.40	15.4	e*

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue Hb 801	6	100.0	0.0	0.0	122.0	4.5	e*
2	Automat	7	85.7	0.0	14.3	106.0	2.4	e
3	Cyanmethemoglobin	14	92.9	0.0	7.1	103.4	3.2	e
4	Sysmex X	62	98.4	0.0	1.6	105.6	1.7	e
5	Hemocue	381	91.1	2.9	6.0	104.3	3.1	e
6	Hemocontrol	14	92.9	0.0	7.1	105.5	1.5	e
7	DiaSpect	14	64.3	0.0	35.7	108.0	3.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	7	100.0	0.0	0.0	106.0	0.7	e
2	Sysmex PocH - 100i	178	98.9	0.0	1.1	104.9	2.3	e
3	Sysmex XP 300	622	98.4	0.2	1.4	105.8	1.7	e
4	Mythic	218	98.6	0.0	1.4	103.0	2.6	e
5	Sysmex XQ-320	181	97.2	0.6	2.2	106.7	1.8	e
6	Swelab	27	96.3	3.7	0.0	111.1	3.2	e
7	Celltac Alpha (Nihon	50	94.0	0.0	6.0	108.1	2.2	e
8	Samsung HC10	5	100.0	0.0	0.0	106.0	3.2	e*
9	Micros 60	53	94.3	0.0	5.7	103.0	3.0	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	4	100.0	0.0	0.0	0.29	2.9	e*
2	Sysmex X	62	98.4	0.0	1.6	0.30	2.8	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	178	96.6	0.0	3.4	0.29	2.5	e
2	Sysmex KX21	7	100.0	0.0	0.0	0.28	2.9	e*
3	Sysmex PocH - 100i	178	99.4	0.0	0.6	0.30	2.5	e
4	Sysmex XP 300	621	97.9	0.3	1.8	0.29	1.9	e
5	Mythic	217	96.8	0.9	2.3	0.29	3.2	e
6	Swelab	27	96.3	3.7	0.0	0.30	4.0	e
7	Celltac Alpha (Nihon	50	86.0	6.0	8.0	0.30	4.0	e
8	Samsung HC10	5	100.0	0.0	0.0	0.32	2.5	e*
9	Micros 60	53	86.8	5.7	7.5	0.27	4.2	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	5	100.0	0.0	0.0	3.51	4.5	e
2	Sysmex X	62	98.4	0.0	1.6	3.47	1.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	179	97.7	0.6	1.7	3.62	3.6	e
2	Sysmex KX21	7	100.0	0.0	0.0	3.52	1.9	e
3	Sysmex PocH - 100i	178	99.4	0.6	0.0	3.63	2.9	e
4	Sysmex XP 300	623	98.3	0.3	1.4	3.50	2.6	e
5	Mythic	216	99.1	0.9	0.0	3.50	4.4	e
6	Swelab	27	100.0	0.0	0.0	3.53	3.2	e
7	Celltac Alpha (Nihon	50	96.0	0.0	4.0	3.66	3.9	e
8	Samsung HC10	5	100.0	0.0	0.0	3.59	2.1	e
9	Micros 60	53	94.3	0.0	5.7	3.40	4.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	4	100.0	0.0	0.0	5.87	9.1	e*
2	Microscopic	4	100.0	0.0	0.0	5.05	14.0	e*
3	Sysmex X	62	100.0	0.0	0.0	6.24	6.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	179	98.3	1.1	0.6	6.23	6.1	e
2	Sysmex KX21	7	100.0	0.0	0.0	5.90	8.5	e*
3	Sysmex PocH - 100i	177	99.4	0.6	0.0	5.88	6.1	e
4	Sysmex XP 300	623	98.6	0.6	0.8	6.04	5.9	e
5	Mythic	217	98.2	0.9	0.9	5.99	6.9	e
6	Swelab	27	96.3	0.0	3.7	6.38	5.1	e
7	Celltac Alpha (Nihon	50	98.0	0.0	2.0	6.41	5.2	e
8	Samsung HC10	5	80.0	0.0	20.0	6.29	5.1	e
9	Micros 60	53	96.2	0.0	3.8	5.89	6.0	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	4	100.0	0.0	0.0	194.8	3.7	e
2	Sysmex X	62	100.0	0.0	0.0	178.8	6.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

Thrombocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	179	97.7	0.6	1.7	174.2	7.7	e
2	Sysmex KX21	7	100.0	0.0	0.0	186.0	8.7	e*
3	Sysmex PocH - 100i	177	99.4	0.6	0.0	193.0	6.1	e
4	Sysmex XP 300	623	99.2	0.5	0.3	195.6	6.0	e
5	Mythic	218	98.6	0.5	0.9	180.2	8.9	e
6	Swelab	27	96.3	3.7	0.0	186.1	11.3	e
7	Celltac Alpha (Nihon	50	96.0	2.0	2.0	192.6	7.2	e
8	Samsung HC10	5	100.0	0.0	0.0	215.0	6.6	e
9	Micros 60	53	90.5	5.7	3.8	183.3	11.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	6	100.0	0.0	0.0	100.0	4.8	e*
2	Microsemi	939	97.0	0.7	2.3	97.6	2.4	e
3	Abx Micros	6	83.3	0.0	16.7	97.0	4.8	e*
4	Z3	252	96.0	0.0	4.0	98.4	3.2	e
5	MEK-1303/5	47	91.5	0.0	8.5	98.9	2.2	e

Hematocrit H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	6	66.6	16.7	16.7	0.27	7.8	e*
2	Microsemi	939	94.9	1.9	3.2	0.26	3.0	e
3	Abx Micros	6	83.3	0.0	16.7	0.26	1.0	e
4	Z3	253	94.8	1.2	4.0	0.28	3.4	e
5	MEK-1303/5	47	89.4	0.0	10.6	0.32	2.5	e

Leucocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	6	100.0	0.0	0.0	5.84	6.3	e
2	Microsemi	939	98.4	0.3	1.3	5.71	5.2	e
3	Abx Micros	6	100.0	0.0	0.0	5.70	3.0	e
4	Z3	253	97.6	1.2	1.2	5.54	6.0	e
5	MEK-1303/5	46	97.8	0.0	2.2	5.91	4.7	e

Thrombocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	6	100.0	0.0	0.0	195.0	8.2	e*
2	Microsemi	938	98.4	0.5	1.1	175.1	7.1	e
3	Abx Micros	6	100.0	0.0	0.0	175.0	9.3	e*
4	Z3	253	97.2	0.4	2.4	185.6	6.9	e
5	MEK-1303/5	46	95.7	0.0	4.3	185.8	6.1	e

Erythrocytes H2



QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	6	100.0	0.0	0.0	3.49	7.8	e*
2	Microsemi	939	96.8	0.3	2.9	3.22	3.6	e
3	Abx Micros	6	83.3	16.7	0.0	3.29	13.3	e*
4	Z3	253	96.0	0.4	3.6	3.18	4.1	e
5	MEK-1303/5	47	91.5	0.0	8.5	3.37	2.8	e

CRP H2



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dymind DP-H10	5	100.0	0.0	0.0	24.9	13.1	e*
2	Microsemi	921	92.6	4.5	2.9	29.7	10.2	e
3	Z3	236	94.1	4.2	1.7	30.6	10.0	e
4	MEK-1303/5	42	90.5	0.0	9.5	24.5	5.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

Hemoglobin BG (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	13	100.0	0.0	0.0	194.2	2.1	e

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	17	100.0	0.0	0.0	0.57	2.7	e
2	EPOC	16	87.5	0.0	12.5	0.49	7.1	a

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	98.4	0.8	0.8	138.0	1.5	e
2	Beckman	5	100.0	0.0	0.0	138.0	1.1	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	140.8	1.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	121	97.5	1.7	0.8	0.42	3.3	e
2	Beckman	5	100.0	0.0	0.0	0.41	2.1	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	0.41	3.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	100.0	0.0	0.0	4.81	2.6	e
2	Beckman	5	100.0	0.0	0.0	4.79	1.2	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	4.81	2.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	121	100.0	0.0	0.0	6.62	6.2	e
2	Beckman	5	80.0	0.0	20.0	6.70	4.8	e
3	Yumizen/Pentra	13	92.3	7.7	0.0	5.27	12.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

Thrombocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	98.4	0.8	0.8	240.1	7.8	e
2	Beckman	5	100.0	0.0	0.0	237.0	4.4	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	232.8	5.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Neutrophils



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	97.5	2.5	0.0	3.76	8.4	e
2	Beckman	5	80.0	0.0	20.0	4.12	2.2	e
3	Yumizen/Pentra	12	83.4	8.3	8.3	2.32	14.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lymphocytes



MQ tolerance : 25 %

Lymphocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	99.2	0.0	0.8	2.12	5.8	e
2	Beckman	5	100.0	0.0	0.0	2.10	13.8	e*
3	Yumizen/Pentra	12	100.0	0.0	0.0	2.35	12.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Monocytes



MQ tolerance : 80 %

Monocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	122	100.0	0.0	0.0	0.50	14.1	e
2	Beckman	5	100.0	0.0	0.0	0.36	21.6	e*
3	Yumizen/Pentra	12	91.7	8.3	0.0	0.42	33.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Eosinophils



MQ tolerance : 80 %
(< 0.13: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	121	100.0	0.0	0.0	0.14	23.9	a
2	Beckman	5	100.0	0.0	0.0	0.20	17.4	e
3	Yumizen/Pentra	12	100.0	0.0	0.0	0.09	48.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Basophiles



MQ tolerance : 80 %
(< 0.13: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	121	100.0	0.0	0.0	0.07	54.1	a
2	Beckman	5	100.0	0.0	0.0	0.01	8.6	e
3	Yumizen/Pentra	12	100.0	0.0	0.0	0.04	78.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCV



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	111	100.0	0.0	0.0	86.6	2.8	e
2	Beckman	4	100.0	0.0	0.0	85.3	1.0	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	85.0	2.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	112	100.0	0.0	0.0	28.7	1.3	e
2	Beckman	4	100.0	0.0	0.0	28.6	1.1	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	29.5	3.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	113	100.0	0.0	0.0	332	3.0	e
2	Beckman	4	100.0	0.0	0.0	334	0.9	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	347	4.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	107	97.2	0.0	2.8	14.1	2.1	e
2	Beckman	4	100.0	0.0	0.0	14.2	1.1	e
3	Yumizen/Pentra	10	100.0	0.0	0.0	14.4	7.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes



MQ tolerance : 25 %
(< 1.30: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	105	95.2	1.0	3.8	0.06	46.0	e*

Reticulocytes



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	67	98.5	0.0	1.5	161.1	9.6	e
2	Advia	4	100.0	0.0	0.0	174.9	7.7	e*
3	Beckman	5	100.0	0.0	0.0	158.1	12.3	e*

Hämolyseindex Probe A



MQ tolerance : 30 %
(< 20.000: +/- 8.000 Index (mg/)

Hämolyseindex Probe A (Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	24	95.8	0.0	4.2	112.913	5.0	e
2	Abbott	7	100.0	0.0	0.0	0.850	14.6	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Hämolyseindex Probe B



MQ tolerance : 30 %
(< 20.000: +/- 8.000 Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	20	95.0	0.0	5.0	0.020	145.7	e*
2	Abbott	7	100.0	0.0	0.0	0.150	14.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lipemia index A



MQ tolerance : 30 %

Lipemia index A (Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	25.00	12.3	e*
2	Abbott	6	83.3	0.0	16.7	27.29	8.9	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipemia index B



MQ tolerance : 30 %

Lipemia index B (Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	88.9	0.0	11.1	454.00	16.3	e*
2	Abbott	6	83.3	0.0	16.7	293.17	9.7	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Icteria Index A



MQ tolerance : 30 %
(< 5.00: +/- 1.50 Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	0.01	0.0	e
2	Abbott	6	100.0	0.0	0.0	1.40	13.0	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Icteria Index B



MQ tolerance : 30 %
(< 5.00: +/- 1.50 Index (mg/)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	0.01	0.0	e
2	Abbott	6	100.0	0.0	0.0	1.54	14.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Erythrocyte sedimentation rate 1h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	28	92.9	7.1	0.0	118	23.0	e
2	Sarstedt Sedivette	18	83.3	5.6	11.1	75	20.5	e*
3	Sarstedt Microvette	4	100.0	0.0	0.0	70	16.1	e*
4	BD Seditainer	42	90.4	4.8	4.8	79	18.8	e
5	Other methods	18	88.9	11.1	0.0	77	21.2	e*

Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	6	100.0	0.0	0.0	115	16.6	e*
2	BD Seditainer	4	100.0	0.0	0.0	115	16.2	e*
3	Other methods	4	100.0	0.0	0.0	123	22.4	e*

Hemoglobin HS



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	25	60.0	0.0	40.0	161.3	2.6	e

Hematocrit HS



MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	25	60.0	0.0	40.0	0.4	2.3	e

Erythrocytes HS



MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	25	60.0	0.0	40.0	4.51	7.3	e

Leucocytes HS



MQ tolerance : 25 %

Leucocytes HS (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	25	100.0	0.0	0.0	7.64	6.2	e

Trombocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	25	100.0	0.0	0.0	245.7	4.4	e

Leucoytes BF



MQ tolerance : 40 %

Leucoytes BF (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	14	100.0	0.0	0.0	0.294	5.6	e

Erythrocytes BF



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	13	100.0	0.0	0.0	72.245	6.4	e

Total cells (TC)



MQ tolerance : 40 %

Total cells (TC) (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	11	100.0	0.0	0.0	0.300	4.9	e

Mononuclear cells (MN)



MQ tolerance : 40 %

Mononuclear cells (MN) (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	13	84.6	15.4	0.0	0.134	38.6	a

Polynuclear cells (PMN)



MQ tolerance : 40 %

Polynuclear cells (PMN) (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	13	84.6	15.4	0.0	0.179	46.9	a

Erythrocyte sedimentation rate



MQ tolerance : 40 %

Erythrocyte sedimentation rate (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	miniiSed	9	100.0	0.0	0.0	19	27.9	a

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	10	90.0	0.0	10.0	35.6	6.6	e
2	Cobas b101	431	97.2	0.9	1.9	32.6	6.3	e
3	Siemens	8	100.0	0.0	0.0	37.2	2.9	e
4	Cobas	44	100.0	0.0	0.0	36.4	5.6	e
5	Turbidimetry	4	100.0	0.0	0.0	39.3	8.0	e*
6	Afinion	1066	99.1	0.5	0.4	37.0	5.0	e
7	NycoCard SingleTest-	48	77.1	8.3	14.6	35.0	11.8	e
8	Quick Read go	85	94.1	2.4	3.5	36.9	7.9	e
9	Eurolyser	53	83.0	5.7	11.3	42.2	10.8	e
10	Fuji Dri-Chem	12	91.7	8.3	0.0	38.1	9.7	e*
11	Piccolo	5	100.0	0.0	0.0	49.1	8.3	e*
12	Celltac chemi	20	90.0	0.0	10.0	35.8	4.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	10	90.0	0.0	10.0	63.4	6.9	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Spinit	7	100.0	0.0	0.0	30.4	2.6	e
2	Abbott	12	100.0	0.0	0.0	37.9	3.3	e
3	Beckman	5	80.0	0.0	20.0	34.1	1.0	e
4	AQT 90 FLEX	5	100.0	0.0	0.0	37.0	6.7	e*
5	Spotchem D-Concept	6	100.0	0.0	0.0	39.9	3.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgG



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	13.10	0.7	e
2	Roche, Cobas	10	100.0	0.0	0.0	13.13	2.6	e
3	Turbidimetry	7	100.0	0.0	0.0	13.10	2.0	e
4	Siemens	5	100.0	0.0	0.0	13.60	4.9	e*
5	Other methods	4	100.0	0.0	0.0	12.25	6.7	e*

IgA



QUALAB tolerance : 15 %

IgA (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	2.40	2.2	e
2	Roche, Cobas	10	100.0	0.0	0.0	2.44	2.3	e
3	Siemens	6	100.0	0.0	0.0	2.67	5.2	e*
4	Turbidimetry	6	100.0	0.0	0.0	2.43	1.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

IgM



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	1.23	5.4	e
2	Siemens	8	100.0	0.0	0.0	1.26	5.4	e*
3	Roche, Cobas	11	100.0	0.0	0.0	1.18	3.8	e

IgE



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	177	4.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Alpha-1-Antitrypsin



MQ tolerance : 25 %

Alpha-1-Antitrypsin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	1.26	4.1	e
2	Roche, Cobas	5	100.0	0.0	0.0	1.26	4.7	e
3	Siemens	5	100.0	0.0	0.0	1.34	1.6	e

Anti-Streptolysin-Antibodies



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	105	3.4	e
2	Roche, Cobas	9	100.0	0.0	0.0	144	5.5	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C3



QUALAB tolerance : 15 %

Complement C3 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	1.66	1.0	e
2	Roche, Cobas	7	100.0	0.0	0.0	1.75	4.4	e
3	Siemens	5	80.0	20.0	0.0	1.74	11.1	e*
4	Other methods	4	100.0	0.0	0.0	1.80	5.3	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C4



QUALAB tolerance : 15 %

Complement C4 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	100.0	0.0	0.0	0.35	2.4	e
2	Roche, Cobas	6	100.0	0.0	0.0	0.32	2.6	e
3	Siemens	5	100.0	0.0	0.0	0.38	3.3	e
4	Other methods	5	100.0	0.0	0.0	0.35	6.6	e*

Haptoglobin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	1.59	1.4	e
2	Roche, Cobas	21	100.0	0.0	0.0	1.62	2.1	e
3	Other methods	4	100.0	0.0	0.0	1.61	1.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Transferrin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	2.23	3.3	e
2	Roche, Cobas	22	100.0	0.0	0.0	2.24	2.5	e
3	Siemens	5	100.0	0.0	0.0	2.21	2.5	e
4	Other methods	5	100.0	0.0	0.0	2.29	3.3	e

Beta-2 microglobuline



MQ tolerance : 25 %

Beta-2 microglobuline (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	1.95	3.3	e
2	Roche, Cobas	6	100.0	0.0	0.0	1.85	3.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Rheumatoid factor



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	30.1	3.9	e
2	Abbott	9	77.8	0.0	22.2	35.4	2.4	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin



MQ tolerance : 25 %

Ceruloplasmin (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	5	100.0	0.0	0.0	344.00	5.2	e
2	Abbott	4	100.0	0.0	0.0	350.00	0.0	e
3	Roche, Cobas	4	100.0	0.0	0.0	250.00	2.3	e

Prealbumin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	100.0	0.0	0.0	209.00	3.1	e
2	all Participants	7	100.0	0.0	0.0	220.00	5.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Soluble transferrin receptor



MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	3.2	1.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain kappa



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	11.00	5.5	e
2	Freelite	12	100.0	0.0	0.0	20.41	8.3	e*

free light chain lambda



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	N Latex	6	100.0	0.0	0.0	10.60	3.2	e
2	Freelite	12	100.0	0.0	0.0	17.88	7.7	e

IgE peanut qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	0.14	45.5	e*

IgE birch qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	15	100.0	0.0	0.0	0.12	57.6	e*

IgE cat qn



QUALAB tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	0.12	58.8	e*

IgE total



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	585	7.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgE sx1 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	11.54	14.7	a

IgE fx5 qn



MQ tolerance : 30 %
(< 1.50: +/- 0.45 kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	0.20	32.4	e*

IgE rx1qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	1.77	17.4	a

IgE rx2 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	2.49	15.8	a

IgE D. pteronyssinus qn



QUALAB tolerance : 30 %

IgE D. pteronyssinus qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	4.64	14.5	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

CRP HS



QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	10	100.0	0.0	0.0	1.71	7.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipoprotein (a)



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	24	4.6	e
2	Others	5	100.0	0.0	0.0	37	7.9	e*

Apolipoprotein A1



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	1.18	5.7	e

Apolipoprotein B



MQ tolerance : 30 %

Apolipoprotein B (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	1.0	5.4	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	204	93.2	3.4	3.4	31.5	8.7	e

Anti deam. Gliadin IgG



MQ tolerance : 30 %
(< 2.00: +/- 1.00 U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Phadia	8	100.0	0.0	0.0	0.50	69.6	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti deam. Gliadin IgA



MQ tolerance : 30 %

Anti deam. Gliadin IgA (U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Phadia	7	100.0	0.0	0.0	4.00	12.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti tTG IgG



MQ tolerance : 30 %
(< 2.00: +/- 1.00 U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	0.80	29.4	e*

Anti tTG IgA



MQ tolerance : 30 %
(< 2.00: +/- 1.00 U/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	0.60	36.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP Lumira



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	11	100.0	0.0	0.0	98.2	7.3	e

Albumine



QUALAB tolerance : 12 %
(< 30.0: +/- 3.6 g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	5	100.0	0.0	0.0	31.0	3.4	e*
2	Abbott	9	100.0	0.0	0.0	34.0	2.3	e
3	Beckman	4	100.0	0.0	0.0	35.0	1.4	e
4	Roche	37	97.3	2.7	0.0	36.3	3.7	e
5	Autolyser	8	87.5	12.5	0.0	35.0	5.2	e*
6	Selectra Pro	10	100.0	0.0	0.0	34.1	3.8	e
7	Fuji Dri-Chem	245	98.8	0.0	1.2	44.2	4.2	e
8	Spotchem D-Concept	235	99.1	0.9	0.0	42.2	5.2	e
9	Spotchem SP-4430	28	96.4	3.6	0.0	41.1	4.7	e
10	Piccolo	63	98.4	0.0	1.6	36.4	4.1	e
11	Skyla	4	100.0	0.0	0.0	36.5	3.9	e*
12	Hitachi S40/M40	4	100.0	0.0	0.0	29.0	1.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Alkaline phosphatase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	130	5.3	e
2	Beckman	6	83.3	16.7	0.0	129	10.7	e*
3	Roche	37	100.0	0.0	0.0	110	4.2	e
4	Siemens	7	100.0	0.0	0.0	114	2.9	e
5	Autolyser	22	100.0	0.0	0.0	113	6.2	e
6	Selectra Pro	15	100.0	0.0	0.0	133	6.6	e
7	Fuji Dri-Chem	1030	98.4	0.8	0.8	132	6.2	e
8	Spotchem D-Concept	559	99.3	0.2	0.5	114	5.3	e
9	Spotchem SP-4430	77	97.4	2.6	0.0	115	7.3	e
10	Piccolo	50	96.0	4.0	0.0	141	6.0	e
11	Skyla	5	100.0	0.0	0.0	151	3.3	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Amylase



QUALAB tolerance : 18 %
(< 50: +/- 9 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	9	100.0	0.0	0.0	174	3.8	e
2	Beckman	4	100.0	0.0	0.0	193	0.7	e
3	Roche	15	100.0	0.0	0.0	178	2.1	e
4	Autolyser	9	100.0	0.0	0.0	160	5.3	e
5	Selectra Pro	10	90.0	10.0	0.0	229	7.7	e*
6	Fuji Dri-Chem	736	99.2	0.7	0.1	137	4.2	e
7	Spotchem D-Concept	396	99.0	1.0	0.0	92	7.0	e
8	Spotchem SP-4430	61	62.2	23.0	14.8	46	16.1	e
9	Piccolo	59	100.0	0.0	0.0	166	4.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	141	2.3	e
2	Roche	17	100.0	0.0	0.0	156	2.2	e
3	Siemens	4	100.0	0.0	0.0	181	8.0	e*
4	Autolyser	10	100.0	0.0	0.0	147	4.2	e

Bilirubin



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	33.9	6.5	e
2	Beckman	6	100.0	0.0	0.0	42.2	5.1	e
3	Roche	37	94.6	5.4	0.0	32.9	7.2	e
4	Siemens	7	100.0	0.0	0.0	43.3	4.2	e
5	Autolyser	19	100.0	0.0	0.0	33.2	5.5	e
6	Selectra Pro	15	86.6	6.7	6.7	30.1	9.3	e*
7	Fuji Dri-Chem	839	95.5	3.3	1.2	37.9	7.9	e
8	Spotchem D-Concept	450	98.0	1.3	0.7	39.7	6.4	e
9	Spotchem SP-4430	72	98.6	0.0	1.4	39.6	6.7	e
10	Piccolo	58	98.3	1.7	0.0	33.2	6.8	e
11	Skyla	7	100.0	0.0	0.0	35.9	7.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin direct



MQ tolerance : 18 %

Bilirubin direct (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	12	100.0	0.0	0.0	23.1	8.9	a
2	Fuji Dri-Chem	22	100.0	0.0	0.0	22.3	6.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium



QUALAB tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	2.22	1.5	e
2	Beckman	5	100.0	0.0	0.0	2.25	3.7	e*
3	Roche	39	100.0	0.0	0.0	2.21	1.9	e
4	Siemens	5	100.0	0.0	0.0	2.20	2.2	e
5	Autolyser	9	100.0	0.0	0.0	2.20	3.4	e*
6	Fuji Dri-Chem	261	95.8	2.3	1.9	2.32	3.9	e
7	Spotchem D-Concept	71	90.2	7.0	2.8	1.60	5.9	e
8	Spotchem SP-4430	12	100.0	0.0	0.0	2.15	3.9	e*
9	Piccolo	50	100.0	0.0	0.0	2.23	2.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	11	100.0	0.0	0.0	0.87	1.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	101	1.9	e
2	Beckman	5	100.0	0.0	0.0	98	0.9	e
3	Roche	29	96.6	0.0	3.4	98	0.8	e
4	Siemens	5	100.0	0.0	0.0	102	1.8	e*
5	Fuji Dri-Chem	950	97.5	1.7	0.8	108	2.0	e
6	Spotchem D-Concept	434	98.3	0.5	1.2	111	1.6	e
7	Spotchem EL-SE 1520	61	80.3	13.1	6.6	117	3.5	e
8	Piccolo	24	100.0	0.0	0.0	101	2.3	e
9	Exias	24	95.8	0.0	4.2	101	1.8	e
10	iStat Chem8	11	100.0	0.0	0.0	107	0.6	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total



QUALAB tolerance : 10 %

Cholesterol total (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	16	100.0	0.0	0.0	3.80	2.2	e
2	Beckman	4	100.0	0.0	0.0	3.72	3.6	e*
3	Roche	31	100.0	0.0	0.0	3.69	2.7	e
4	Siemens	4	75.0	0.0	25.0	3.72	2.6	e*
5	Autolyser	22	95.5	4.5	0.0	3.72	3.9	e
6	Selectra Pro	13	92.3	0.0	7.7	3.78	3.1	e
7	Fuji Dri-Chem	981	97.1	1.2	1.7	3.47	3.7	e
8	Spotchem D-Concept	479	97.9	1.3	0.8	3.66	3.5	e
9	Spotchem SP-4430	76	97.4	1.3	1.3	3.50	3.8	e
10	Piccolo	26	100.0	0.0	0.0	3.78	3.1	e
11	Reflotron	4	100.0	0.0	0.0	3.41	7.8	e*
12	Cholestech LDX	256	96.1	3.1	0.8	3.55	4.3	e
13	Other methods	4	100.0	0.0	0.0	2.89	1.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterin HDL



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	0.84	6.3	e
2	Beckman	6	100.0	0.0	0.0	1.10	4.2	e
3	Roche	29	100.0	0.0	0.0	0.81	4.1	e
4	Dimension	5	100.0	0.0	0.0	1.49	5.0	e
5	Autolyser	22	100.0	0.0	0.0	1.47	8.0	e
6	Selectra Pro	12	58.4	8.3	33.3	1.35	13.1	e*
7	Fuji Dri-Chem	948	98.4	0.3	1.3	1.31	4.0	e
8	Spotchem D-Concept	464	93.9	3.7	2.4	0.55	10.2	e
9	Spotchem SP-4430	69	91.4	4.3	4.3	0.51	10.6	e
10	Piccolo	25	96.0	4.0	0.0	0.93	8.8	e
11	Cholestech LDX	255	86.7	7.8	5.5	0.87	12.1	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatine kinase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	252	2.0	e
2	Beckman	5	100.0	0.0	0.0	249	2.2	e
3	Roche	34	100.0	0.0	0.0	242	2.2	e
4	Siemens	7	100.0	0.0	0.0	239	2.4	e
5	Autolyser	17	94.1	0.0	5.9	269	4.0	e
6	Selectra Pro	8	100.0	0.0	0.0	250	2.0	e
7	Fuji Dri-Chem	666	98.7	0.5	0.8	267	4.8	e
8	Spotchem D-Concept	319	95.3	3.1	1.6	205	8.4	e
9	Spotchem SP-4430	38	97.4	0.0	2.6	246	7.5	e
10	Piccolo	20	95.0	5.0	0.0	250	5.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Cholesterol LDL



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	2.0	3.4	e
2	Beckman	5	100.0	0.0	0.0	2.5	4.5	e
3	Roche, Cobas	17	100.0	0.0	0.0	2.6	3.6	e
4	Autolyser	11	90.9	0.0	9.1	2.5	4.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Iron



QUALAB tolerance : 20 %

Iron (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	12	100.0	0.0	0.0	32	3.3	e
2	Roche	23	100.0	0.0	0.0	32	1.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Gamma-glutamyltransferase



QUALAB tolerance : 18 %

Gamma-glutamyltransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	59	4.2	e
2	Beckman	6	100.0	0.0	0.0	54	3.2	e
3	Cobas	38	100.0	0.0	0.0	51	6.9	e
4	Siemens	7	100.0	0.0	0.0	57	6.3	e*
5	Autolyser	22	100.0	0.0	0.0	53	4.3	e
6	Selectra Pro	14	100.0	0.0	0.0	51	5.4	e
7	Fuji Dri-Chem	1144	99.1	0.3	0.6	64	5.1	e
8	Spotchem D-Concept	630	99.0	0.5	0.5	61	6.0	e
9	Spotchem SP-4430	125	97.6	0.8	1.6	66	7.2	e
10	Piccolo	62	100.0	0.0	0.0	47	6.8	e
11	Skyla	5	100.0	0.0	0.0	49	3.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	8.6	1.7	e
2	Beckman	6	83.3	16.7	0.0	8.9	4.6	e*
3	Roche	40	100.0	0.0	0.0	8.7	2.0	e
4	Siemens	6	100.0	0.0	0.0	8.7	3.2	e*
5	Autolyser	20	95.0	0.0	5.0	8.5	3.6	e
6	Selectra Pro	14	100.0	0.0	0.0	8.9	3.5	e
7	Fuji Dri-Chem	1083	98.8	0.5	0.7	8.2	2.5	e
8	Spotchem D-Concept	592	94.3	5.4	0.3	8.5	4.4	e
9	Spotchem SP-4430	102	95.1	2.9	2.0	8.7	4.5	e
10	Piccolo	75	100.0	0.0	0.0	8.7	1.2	e
11	Cholestech LDX	253	92.5	2.8	4.7	8.4	4.3	e
12	iStat Chem8	12	100.0	0.0	0.0	7.9	1.9	e
13	Cobas Pulse	137	98.5	1.5	0.0	8.4	3.5	e
14	Other methods	4	100.0	0.0	0.0	8.9	3.5	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	143	97.2	2.1	0.7	8.1	3.3	e
2	Accu-Chek Aviva	100	87.0	6.0	7.0	9.4	4.0	e
3	Accu-Chek Inform 2	949	97.3	1.5	1.2	10.2	3.3	e
4	Accu-Check Guide	343	97.9	0.9	1.2	8.2	3.0	e
5	Contour XT	1338	94.8	3.8	1.4	8.9	4.1	e
6	Skyla	5	100.0	0.0	0.0	8.8	1.4	e
7	Statstrip/Xpress	66	100.0	0.0	0.0	7.9	2.9	e
8	Glucocard	7	42.8	14.3	42.9	12.2	6.3	e*
9	Hemocue 201+ P-equiv	145	94.5	1.4	4.1	10.5	2.8	e
10	Hemocue 201RT P-equi	132	97.7	1.5	0.8	10.4	2.6	e
11	Contour NEXT	60	98.3	1.7	0.0	8.4	4.2	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OneTouch Verio	29	100.0	0.0	0.0	8.6	2.5	e
2	Contour 2 (5s)	8	87.5	0.0	12.5	7.1	1.8	e
3	Healthpro	20	95.0	0.0	5.0	14.9	4.2	e
4	Mylife UNIO	237	95.4	2.5	2.1	10.1	4.2	e
5	mylife Pura	87	78.2	13.8	8.0	9.9	5.7	e
6	Alpha Check	34	88.2	5.9	5.9	14.1	5.1	e

Uric Acid



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	333	2.8	e
2	Beckman	6	100.0	0.0	0.0	345	1.4	e
3	Roche	35	100.0	0.0	0.0	332	2.2	e
4	Siemens	5	100.0	0.0	0.0	352	4.7	e*
5	Autolyser	18	100.0	0.0	0.0	341	4.1	e
6	Selectra Pro	15	93.3	0.0	6.7	334	2.5	e
7	Fuji Dri-Chem	1051	98.7	0.3	1.0	368	2.8	e
8	Spotchem D-Concept	594	99.3	0.5	0.2	314	4.1	e
9	Spotchem SP-4430	97	96.9	2.1	1.0	274	4.1	e
10	Piccolo	34	91.2	2.9	5.9	258	5.0	e
11	Skyla	9	100.0	0.0	0.0	340	5.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Urea



QUALAB tolerance : 15 %

Urea (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	10.0	4.2	e
2	Beckman	6	100.0	0.0	0.0	9.9	6.2	e*
3	Roche	35	100.0	0.0	0.0	9.6	3.1	e
4	Siemens	7	100.0	0.0	0.0	9.7	3.5	e
5	Autolyser	17	100.0	0.0	0.0	10.1	4.0	e
6	Selectra Pro	11	100.0	0.0	0.0	10.0	6.3	e*
7	Fuji Dri-Chem	625	98.7	0.2	1.1	10.2	2.3	e
8	Spotchem D-Concept	329	96.4	1.8	1.8	9.8	6.6	e
9	Spotchem SP-4430	50	96.0	4.0	0.0	10.0	6.5	e
10	Piccolo	67	100.0	0.0	0.0	8.7	3.3	e
11	Skyla	5	100.0	0.0	0.0	9.8	1.7	e
12	iStat Chem8	9	100.0	0.0	0.0	13.2	2.7	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium



QUALAB tolerance : 6 %
(< 3.30: +/- 0.20 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	3.58	1.3	e
2	Beckman	6	100.0	0.0	0.0	3.60	1.3	e
3	Roche	38	100.0	0.0	0.0	3.61	1.1	e
4	Siemens	5	100.0	0.0	0.0	3.50	0.0	e
5	Autolyser	18	94.4	5.6	0.0	3.51	3.7	e*
6	Fuji Dri-Chem	1113	98.7	0.3	1.0	3.50	1.8	e
7	Spotchem D-Concept	556	97.7	0.9	1.4	3.20	1.5	e
8	Spotchem EL-SE 1520	78	94.9	1.3	3.8	3.18	2.4	e
9	Piccolo	38	79.0	10.5	10.5	3.70	4.6	e*
10	iStat Chem8	15	100.0	0.0	0.0	3.50	1.1	e
11	Exias	27	100.0	0.0	0.0	3.60	1.0	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	260	2.6	e
2	Beckman	6	100.0	0.0	0.0	261	0.8	e
3	Roche	37	100.0	0.0	0.0	256	2.9	e
4	Siemens	7	85.7	0.0	14.3	263	3.0	e
5	Enzymatic	4	100.0	0.0	0.0	265	3.6	e
6	Autolyser	22	100.0	0.0	0.0	253	3.7	e
7	Selectra Pro	15	100.0	0.0	0.0	254	4.1	e
8	Fuji Dri-Chem	1175	99.1	0.3	0.6	233	4.3	e
9	Spotchem D-Concept	649	99.2	0.2	0.6	127	4.3	e
10	Spotchem SP-4430	143	97.9	0.7	1.4	128	4.1	e
11	Piccolo	71	98.6	0.0	1.4	263	4.3	e
12	Skyla	5	100.0	0.0	0.0	231	6.8	e*
13	EPOC	12	83.3	0.0	16.7	237	6.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine E



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	46	100.0	0.0	0.0	262	2.9	e
2	ABL700/800	15	100.0	0.0	0.0	260	5.6	e

eGFR CKD-EPI



MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	57	98.2	1.8	0.0	23	7.3	e
2	Fuji Dri-Chem	393	96.1	0.8	3.1	27	6.8	e
3	Spotchem	262	94.6	2.3	3.1	56	9.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

eGFR Cockcroft-Gault



MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	35	80.0	5.7	14.3	33	19.9	e
2	Spotchem	17	94.1	0.0	5.9	62	11.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

LDH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	166	6.1	e
2	Beckman	5	100.0	0.0	0.0	173	5.2	e*
3	Roche	36	100.0	0.0	0.0	177	2.3	e
4	Siemens	4	100.0	0.0	0.0	167	5.6	e*
5	Autolyser	7	85.7	14.3	0.0	180	9.8	e*
6	Fuji Dri-Chem	113	97.3	0.9	1.8	146	4.8	e
7	Spotchem D-Concept	42	90.4	4.8	4.8	102	9.5	e
8	Spotchem SP-4430	13	92.3	0.0	7.7	100	9.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Magnesium



QUALAB tolerance : 12 %
(< 0.70: +/- 0.09 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	0.86	2.5	e
2	Beckman	4	100.0	0.0	0.0	0.86	2.5	e
3	Roche	30	96.7	3.3	0.0	0.88	3.6	e
4	Siemens	4	75.0	0.0	25.0	0.88	2.3	e
5	Fuji Dri-Chem	73	93.2	4.1	2.7	0.95	4.7	e
6	Spotchem D-Concept	39	100.0	0.0	0.0	0.70	5.2	e
7	Spotchem SP-4430	4	100.0	0.0	0.0	0.72	3.3	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser	8	100.0	0.0	0.0	144	2.1	e*
2	Abbott	16	93.7	0.0	6.3	139	1.0	e
3	Beckman	6	100.0	0.0	0.0	138	0.8	e
4	Roche	38	100.0	0.0	0.0	139	0.9	e
5	Siemens	5	100.0	0.0	0.0	137	1.4	e
6	Fuji Dri-Chem	1029	98.5	0.9	0.6	142	1.4	e
7	Spotchem D-Concept	481	99.6	0.0	0.4	134	1.1	e
8	Spotchem EL-SE 1520	67	94.0	1.5	4.5	133	2.0	e
9	Piccolo	35	100.0	0.0	0.0	136	1.6	e
10	Exias	28	100.0	0.0	0.0	139	1.0	e
11	iStat Chem8	15	100.0	0.0	0.0	138	0.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Phosphate



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	15	100.0	0.0	0.0	1.38	2.3	e
2	Beckman	4	100.0	0.0	0.0	1.41	2.6	e
3	Roche	35	100.0	0.0	0.0	1.38	2.7	e
4	Siemens	4	100.0	0.0	0.0	1.46	1.5	e
5	Fuji Dri-Chem	68	91.1	1.5	7.4	1.45	5.3	e
6	Spotchem D-Concept	14	100.0	0.0	0.0	1.43	4.0	e
7	Piccolo	4	100.0	0.0	0.0	1.73	2.2	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein total



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	14	100.0	0.0	0.0	54.6	2.6	e
2	Beckman	4	100.0	0.0	0.0	54.9	0.8	e
3	Roche	32	100.0	0.0	0.0	54.0	2.6	e
4	Siemens	5	100.0	0.0	0.0	57.0	2.4	e
5	Autolyser	4	100.0	0.0	0.0	54.2	8.1	e*
6	Selectra Pro	8	87.5	0.0	12.5	52.4	4.2	e*
7	Fuji Dri-Chem	183	97.8	0.0	2.2	53.0	3.6	e
8	Spotchem D-Concept	187	92.0	5.3	2.7	55.8	5.9	e
9	Spotchem SP-4430	23	95.7	4.3	0.0	57.7	5.2	e
10	Piccolo	47	100.0	0.0	0.0	54.8	1.6	e
11	Skyla	5	100.0	0.0	0.0	57.0	2.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Aspartate aminotransferase



QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Vitros	4	100.0	0.0	0.0	103	10.4	e*
2	Abbott	15	100.0	0.0	0.0	105	4.1	e
3	Beckman	6	100.0	0.0	0.0	106	4.8	e
4	Roche	39	100.0	0.0	0.0	101	3.8	e
5	Siemens	5	100.0	0.0	0.0	100	5.9	e*
6	Autolyser	22	100.0	0.0	0.0	93	4.9	e
7	Selectra Pro	15	93.3	0.0	6.7	103	7.1	e
8	Fuji Dri-Chem	1150	98.7	0.5	0.8	99	4.3	e
9	Spotchem D-Concept	634	99.5	0.0	0.5	70	4.3	e
10	Spotchem SP-4430	135	99.3	0.0	0.7	70	5.4	e
11	Piccolo	73	98.6	1.4	0.0	90	4.0	e
12	Skyla	5	100.0	0.0	0.0	102	4.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Alanine aminotransferase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Vitros	5	100.0	0.0	0.0	105	6.0	e*
2	Abbott	13	100.0	0.0	0.0	74	4.5	e
3	Beckman	6	100.0	0.0	0.0	83	4.3	e
4	Roche	39	100.0	0.0	0.0	80	3.3	e
5	Siemens	7	85.7	14.3	0.0	89	12.0	e*
6	Autolyser	22	100.0	0.0	0.0	81	3.7	e
7	Selectra Pro	15	100.0	0.0	0.0	89	6.0	e
8	Fuji Dri-Chem	1169	98.2	0.9	0.9	84	5.5	e
9	Spotchem D-Concept	639	96.9	2.2	0.9	60	7.6	e
10	Spotchem SP-4430	136	99.3	0.0	0.7	69	5.7	e
11	Piccolo	70	97.1	2.9	0.0	73	6.0	e
12	Skyla	5	100.0	0.0	0.0	82	1.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Triglycerides



QUALAB tolerance : 18 %

Triglycerides (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	1.98	1.6	e
2	Beckman	5	100.0	0.0	0.0	2.10	3.6	e
3	Roche	31	100.0	0.0	0.0	2.09	2.5	e
4	Siemens	6	100.0	0.0	0.0	2.05	4.2	e
5	Autolyser	23	100.0	0.0	0.0	1.94	4.5	e
6	Selectra Pro	12	100.0	0.0	0.0	2.11	2.8	e
7	Fuji Dri-Chem	963	99.0	0.3	0.7	2.55	4.7	e
8	Spotchem D-Concept	461	98.3	0.2	1.5	1.26	4.5	e
9	Spotchem SP-4430	72	100.0	0.0	0.0	1.23	3.8	e
10	Piccolo	23	100.0	0.0	0.0	2.38	3.5	e
11	Cholestech LDX	256	99.2	0.4	0.4	1.97	4.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium



QUALAB tolerance : 15 %

Lithium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	1.29	1.9	e
2	Roche	17	94.1	0.0	5.9	1.32	3.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	3.27	2.1	e
2	Roche	17	100.0	0.0	0.0	3.16	3.2	e
3	Other methods	7	71.4	14.3	14.3	3.15	8.6	e*

HbA1c sample A



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	8.2	2.3	e*
2	Roche, Cobas	21	100.0	0.0	0.0	8.2	2.1	e
3	HPLC	13	100.0	0.0	0.0	8.1	2.4	e
4	Afinion	530	97.6	0.9	1.5	8.0	2.6	e
5	Cobas b101	217	98.6	0.5	0.9	7.6	3.1	e
6	DCA2000/Vantage	139	97.9	1.4	0.7	8.0	3.4	e
7	Celltac chemi	23	87.0	4.3	8.7	7.8	4.9	e
8	NycoCard	5	100.0	0.0	0.0	8.1	4.8	e*
9	Eurolyser	7	100.0	0.0	0.0	8.2	5.3	e*
10	A1c Now	220	87.3	8.6	4.1	7.2	5.3	e
11	AFIAS	128	71.9	20.3	7.8	7.4	7.0	e
12	Others	18	88.9	11.1	0.0	8.1	4.5	c

4 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	7.1	2.4	e*
2	Roche, Cobas	18	100.0	0.0	0.0	7.0	3.1	e
3	HPLC	13	100.0	0.0	0.0	6.9	2.4	e
4	Afinion	733	98.8	0.5	0.7	6.7	2.3	e
5	Cobas b101	210	98.5	1.0	0.5	6.6	3.0	e
6	DCA2000/Vantage	189	96.8	1.6	1.6	6.9	3.5	e
7	Celltac chemi	21	100.0	0.0	0.0	6.7	4.1	e
8	NycoCard	4	100.0	0.0	0.0	7.1	3.6	e*
9	Eurolyser	5	80.0	20.0	0.0	6.9	5.5	e*
10	A1c Now	7	57.1	14.3	28.6	6.9	4.9	c
11	AFIAS	191	69.6	21.5	8.9	6.5	6.3	e
12	Others	12	100.0	0.0	0.0	6.9	3.5	c

6 additional results were submitted but not published because the method groups were too small. (< results per group)

pCO2



QUALAB tolerance : 12 %

pCO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Edan	4	100.0	0.0	0.0	3.27	7.9	e*
2	ABL700/800	108	100.0	0.0	0.0	2.85	2.6	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	3.07	6.1	e*
4	ABL90 FLEX / PLUS	129	99.2	0.8	0.0	2.94	2.3	e
5	Cobas b 123	19	94.7	0.0	5.3	3.00	2.3	e
6	Cobas b 221	4	100.0	0.0	0.0	3.04	2.7	e
7	GEM	8	100.0	0.0	0.0	2.80	1.3	e
8	iStat	51	98.0	0.0	2.0	2.50	4.3	e
9	EPOC	55	89.1	9.1	1.8	2.44	6.2	e
10	IL	4	100.0	0.0	0.0	2.80	2.9	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

pO2



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Edan	4	100.0	0.0	0.0	12.50	12.6	a
2	ABL700/800	107	92.6	0.9	6.5	9.93	5.0	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	8.07	6.8	e*
4	ABL90 FLEX / PLUS	131	90.1	1.5	8.4	7.47	4.5	e
5	Cobas b 123	20	90.0	5.0	5.0	9.19	7.6	e
6	GEM	8	87.5	12.5	0.0	9.52	8.7	e*
7	iStat	48	85.4	8.3	6.3	11.57	8.5	e
8	EPOC	55	63.7	21.8	14.5	9.93	11.5	e
9	IL	4	100.0	0.0	0.0	9.55	5.2	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

pH



QUALAB tolerance : 1 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	106	100.0	0.0	0.0	7.57	0.1	e
2	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	7.59	0.3	e*
3	ABL90 FLEX / PLUS	131	100.0	0.0	0.0	7.59	0.1	e
4	Cobas b 123	20	100.0	0.0	0.0	7.58	0.1	e
5	Cobas b 221	4	100.0	0.0	0.0	7.57	0.2	e
6	GEM	8	100.0	0.0	0.0	7.63	0.1	e
7	iStat	53	100.0	0.0	0.0	7.65	0.1	e
8	EPOC	55	100.0	0.0	0.0	7.66	0.1	e
9	IL	4	100.0	0.0	0.0	7.64	0.1	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG



QUALAB tolerance : 9 %

Glucose BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	5	100.0	0.0	0.0	14.6	0.8	e
2	Cobas b 123	12	100.0	0.0	0.0	14.6	2.0	e
3	iStat	10	100.0	0.0	0.0	13.4	1.2	e
4	EPOC	44	95.5	4.5	0.0	14.1	4.3	e
5	ABL700/800	98	99.0	0.0	1.0	14.0	2.4	e
6	ABL90 FLEX / PLUS	119	99.2	0.8	0.0	13.6	2.1	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	100	100.0	0.0	0.0	189.9	1.6	e
2	ABL90 FLEX / PLUS	119	100.0	0.0	0.0	190.0	0.4	e
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	186.0	1.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium BG



QUALAB tolerance : 6 %

Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	5.7	1.0	e
2	Cobas b 123	21	100.0	0.0	0.0	5.4	0.6	e
3	iStat	18	100.0	0.0	0.0	5.3	0.9	e
4	EPOC	45	97.8	2.2	0.0	4.8	2.5	e
5	ABL700/800	99	100.0	0.0	0.0	5.5	1.2	e
6	ABL90 FLEX / PLUS	123	98.4	0.0	1.6	5.4	0.7	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	7	100.0	0.0	0.0	122.0	0.4	e
2	Cobas b 123	21	100.0	0.0	0.0	122.0	1.3	e
3	iStat	18	100.0	0.0	0.0	124.1	0.5	e
4	EPOC	43	100.0	0.0	0.0	120.3	1.0	e
5	ABL700/800	98	100.0	0.0	0.0	126.7	0.8	e
6	ABL90 FLEX / PLUS	122	100.0	0.0	0.0	126.0	0.3	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	14	100.0	0.0	0.0	70.3	0.9	e
2	EPOC	19	84.2	15.8	0.0	73.5	3.3	e*
3	ABL700/800	93	95.7	3.2	1.1	67.7	2.9	e
4	ABL90 FLEX / PLUS	118	100.0	0.0	0.0	64.4	1.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG



MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	0.28	2.3	e
2	Cobas b123	12	100.0	0.0	0.0	0.18	31.6	e*
3	Roche, Cobas	4	100.0	0.0	0.0	0.22	35.1	e*
4	iStat	15	100.0	0.0	0.0	0.31	1.7	e
5	EPOC	41	97.6	0.0	2.4	0.29	5.1	e
6	ABL700/800	98	100.0	0.0	0.0	0.37	4.5	e
7	ABL90 FLEX / PLUS	120	100.0	0.0	0.0	0.38	1.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	18	100.0	0.0	0.0	20.908	0.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate-BG



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	6	100.0	0.0	0.0	11.80	1.3	e
2	Cobas b123	13	100.0	0.0	0.0	10.65	6.7	e
3	IL	4	100.0	0.0	0.0	11.30	4.9	e*
4	EPOC	43	95.3	0.0	4.7	9.84	5.4	e
5	iStat	19	100.0	0.0	0.0	10.71	1.8	e
6	ABL700/800	102	100.0	0.0	0.0	10.31	4.6	e
7	ABL90 FLEX / PLUS	126	100.0	0.0	0.0	10.50	1.8	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

sO2 OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	26	100.0	0.0	0.0	98.577	0.6	e
2	ABL700/800	89	100.0	0.0	0.0	70.103	0.1	e
3	ABL90 FLEX / PLUS	109	100.0	0.0	0.0	70.100	0.1	e
4	ABL80 FLEX CO-OX / O	4	75.0	0.0	25.0	70.100	0.2	e

FO2Hb OR



MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	87	100.0	0.0	0.0	48.855	0.3	e
2	ABL90 FLEX / PLUS	110	100.0	0.0	0.0	48.936	0.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FCOHb OR



MQ tolerance : 20 %

FCOHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	100.0	0.0	0.0	20.301	1.1	e
2	ABL90 FLEX / PLUS	110	100.0	0.0	0.0	20.183	0.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FMetHb OR



MQ tolerance : 20 %

FMetHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	88	98.9	0.0	1.1	10.009	0.9	e
2	ABL90 FLEX / PLUS	110	100.0	0.0	0.0	9.999	1.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FHbF OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	37	100.0	0.0	0.0	52.243	2.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin OR



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	5	100.0	0.0	0.0	439.0	2.6	e
2	ABL90 FLEX / PLUS	34	100.0	0.0	0.0	438.6	0.5	e

Troponin I



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	24	91.7	0.0	8.3	3021.8	9.3	e
2	Siemens	4	100.0	0.0	0.0	3117.8	2.6	e
3	Vidas	12	100.0	0.0	0.0	6036.8	8.2	e
4	Abbott	8	100.0	0.0	0.0	855.7	5.0	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin T



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	10	100.0	0.0	0.0	569.46	6.9	e
2	Cobas hs STAT	20	100.0	0.0	0.0	498.82	7.7	e

Myoglobin



QUALAB tolerance : 30 %

Myoglobin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	72.3	4.8	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass



MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	13.4	4.6	e
2	Cobas E / Elecsys	10	100.0	0.0	0.0	15.3	3.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	80.0	0.0	20.0	356.7	14.2	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-proBNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	17	100.0	0.0	0.0	1557.1	11.4	e
2	VIDAS	9	100.0	0.0	0.0	543.0	7.4	e
3	Cobas E / Elecsys	25	100.0	0.0	0.0	541.6	5.5	e
4	Abbott	8	100.0	0.0	0.0	594.9	6.3	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

TSH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	32	100.0	0.0	0.0	3.66	3.3	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	3.32	6.6	e*
3	Abbott	11	100.0	0.0	0.0	2.86	4.2	e
4	VIDAS	16	100.0	0.0	0.0	3.94	8.6	a
5	Dimension	6	100.0	0.0	0.0	3.13	6.0	e*
6	AFIAS	18	83.3	16.7	0.0	5.41	11.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

T3



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	2.0	5.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

T4



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	5	100.0	0.0	0.0	126	6.1	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

FT3



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	28	100.0	0.0	0.0	6.6	2.8	e
2	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	5.6	1.5	e
3	Abbott	9	100.0	0.0	0.0	5.7	3.8	e
4	VIDAS	8	100.0	0.0	0.0	5.0	7.3	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	28	100.0	0.0	0.0	23.6	2.9	e
2	ADVIA Centaur XP	8	100.0	0.0	0.0	19.2	5.0	e
3	Abbott	10	100.0	0.0	0.0	17.3	4.9	e
4	VIDAS	9	100.0	0.0	0.0	20.6	4.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone



QUALAB tolerance : 30 %

Testosterone (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	15	100.0	0.0	0.0	9.3	4.1	e
2	Siemens	7	100.0	0.0	0.0	8.6	11.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	765	3.3	e
2	Siemens	6	100.0	0.0	0.0	1011	11.8	e*
3	Other methods	5	100.0	0.0	0.0	640	15.3	e*
4	Abbott	4	100.0	0.0	0.0	672	3.1	e

SHBG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	26.8	3.9	e
2	Abbott	5	100.0	0.0	0.0	31.0	15.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol



QUALAB tolerance : 20 %

Cortisol (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	22	100.0	0.0	0.0	349	2.9	e
2	Abbott	5	100.0	0.0	0.0	343	2.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	21.1	2.8	e
2	Abbott	5	100.0	0.0	0.0	16.9	7.8	e
3	Other methods	5	100.0	0.0	0.0	20.8	16.9	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

DHEAS



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	4.56	3.9	e
2	Abbott	4	100.0	0.0	0.0	4.04	13.1	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Luteinizing hormone



QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	15	100.0	0.0	0.0	14.8	5.8	e
2	Siemens	5	100.0	0.0	0.0	12.3	5.2	e
3	Abbott	4	100.0	0.0	0.0	9.7	3.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Follicle-stimulating hormone



QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	11.8	2.9	e
2	Abbott	7	100.0	0.0	0.0	11.5	2.6	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Prolactin (PRL)



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	8.9	5.5	e
2	Cobas/Roche	15	100.0	0.0	0.0	15.2	3.4	e
3	Abbott	5	100.0	0.0	0.0	13.5	9.9	e*

Insulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	16	100.0	0.0	0.0	318	5.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HGH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	8.09	3.2	e
2	Liaison	4	100.0	0.0	0.0	7.43	7.7	e*

Freies Testosteron



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IDS	6	100.0	0.0	0.0	31.4	10.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Androstendion



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	3.4	11.9	e*

IGF-1



MQ tolerance : 25 %

IGF-1 (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	8	100.0	0.0	0.0	88	12.5	e*
2	Other methods	4	100.0	0.0	0.0	63	0.8	e

17-OH-Progesteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	3.9	19.0	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Troponin T CR



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	772	88.4	8.0	3.6	141.92	13.7	e

D-dimer CR



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	896	87.0	9.5	3.5	0.42	13.6	e
2	Lumira Dx	7	85.7	0.0	14.3	0.46	6.7	e*

CKMB- K8



MQ tolerance : 40 %

CKMB- K8 (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	6	100.0	0.0	0.0	15.8	12.0	e*

NT-proBNP CR



QUALAB tolerance : 27 %

NT-proBNP CR (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	5	100.0	0.0	0.0	374	7.1	e
2	Cobas h 232	542	90.2	4.8	5.0	103	12.0	e

PCO2 CCA



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	81.8	0.0	18.2	9.33	3.1	e

PO2 CCA



QUALAB tolerance : 15 %

PO2 CCA (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	11	81.8	9.1	9.1	9.48	7.3	e*

pH CCA



QUALAB tolerance : 1 %

pH CCA ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	10	90.0	10.0	0.0	7.15	0.4	e*

Potassium CCA



QUALAB tolerance : 6 %
(< 3.3: +/- 0.2 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	5	100.0	0.0	0.0	2.9	1.7	e*

Sodium CCA



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	4	100.0	0.0	0.0	125.4	1.0	e

Ferritin



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	5	100.0	0.0	0.0	38.00	5.2	e
2	Beckman	5	80.0	20.0	0.0	34.40	16.6	e*
3	Siemens	4	100.0	0.0	0.0	25.10	2.5	e
4	Roche, Cobas	30	100.0	0.0	0.0	37.36	6.3	e
5	Abbott	14	92.9	7.1	0.0	36.06	12.3	e*
6	Mini Vidas	9	88.9	11.1	0.0	26.10	14.1	e*
7	AFIAS	25	100.0	0.0	0.0	28.08	5.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12



QUALAB tolerance : 21 %
(< 200.00: +/- 42.00 pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	184.00	9.9	e*
2	Roche, Cobas	22	100.0	0.0	0.0	202.31	6.7	e
3	Abbott	10	90.0	0.0	10.0	192.67	11.3	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate



QUALAB tolerance : 24 %
(< 10.00: +/- 2.40 nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	8	100.0	0.0	0.0	4.00	22.0	e*
2	Roche, Cobas	24	100.0	0.0	0.0	4.11	21.6	e*
3	Abbott	10	90.0	0.0	10.0	7.58	10.5	e*

Holotranscobalamine



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	35	100.0	0.0	0.0	41.3	3.5	e
2	Abbott	16	100.0	0.0	0.0	51.6	5.2	e
3	Cobas Biotin suppres	4	100.0	0.0	0.0	25.5	3.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin total Neo



QUALAB tolerance : 18 %

Bilirubin total Neo (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	227	4.4	e
2	Dimension	6	100.0	0.0	0.0	273	3.6	e

Bilirubin direct



QUALAB tolerance : 18 %

Bilirubin direct (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	19	94.7	0.0	5.3	144	4.0	e
2	Dimension	4	100.0	0.0	0.0	136	1.4	e

Bilirubin neonatal



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	14	100.0	0.0	0.0	274	3.9	e
2	Other methods	12	100.0	0.0	0.0	293	2.9	e

PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	19	100.0	0.0	0.0	7.48	4.9	e
2	Abbott	7	100.0	0.0	0.0	7.02	4.8	e
3	AFIAS	10	100.0	0.0	0.0	7.42	7.2	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	1.59	3.6	e
2	Siemens	4	100.0	0.0	0.0	1.74	7.2	e*
3	Abbott	6	100.0	0.0	0.0	1.67	8.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	100.0	0.0	0.0	5.5	4.4	e
2	Abbott	6	100.0	0.0	0.0	7.3	7.1	e*

7 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	10	100.0	0.0	0.0	57.0	4.3	e
2	Abbott	6	100.0	0.0	0.0	92.2	2.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	32.3	4.1	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3



MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	12	100.0	0.0	0.0	21.0	6.6	e
2	Siemens	4	100.0	0.0	0.0	21.5	5.3	e
3	Abbott	6	100.0	0.0	0.0	24.3	4.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

AFP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	100.0	0.0	0.0	9.7	9.6	e*
2	Abbott	4	100.0	0.0	0.0	8.4	3.4	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	33.2	4.9	e
2	VIDAS	11	100.0	0.0	0.0	10.8	10.1	e*
3	Abbott	6	100.0	0.0	0.0	35.3	8.5	d
4	AFIAS	7	100.0	0.0	0.0	55.0	13.5	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	9.7	5.1	e

S100



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	0.56	6.3	e

NSE



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	6.6	6.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	52.0	6.5	e
2	Other methods	4	100.0	0.0	0.0	87.3	12.5	e*

CK-MB



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	19	100.0	0.0	0.0	67.5	6.1	e
2	Cobas/Roche	7	85.7	0.0	14.3	41.0	4.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

C-Peptid



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	85.7	0.0	14.3	3.94	7.1	e
2	Other methods	5	100.0	0.0	0.0	3.43	9.8	e*

ACTH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	100.0	0.0	0.0	25.39	13.7	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Procalcitonin



QUALAB tolerance : 27 %

Procalcitonin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	4	100.0	0.0	0.0	13.46	4.0	e
2	Cobas	19	100.0	0.0	0.0	10.86	5.2	e
3	VIDAS	15	100.0	0.0	0.0	8.18	5.2	e
4	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	14.19	4.9	e
5	Other methods	4	100.0	0.0	0.0	24.50	20.9	a

6 additional results were submitted but not published because the method groups were too small. (< results per group)

EPO



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	218.9	10.7	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone



QUALAB tolerance : 24 %

Parathyroid hormone (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	9	100.0	0.0	0.0	35.4	5.2	e
2	Cobas	15	100.0	0.0	0.0	28.6	5.5	e
3	Abbott	6	100.0	0.0	0.0	63.4	6.7	e
4	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	65.6	5.9	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



QUALAB tolerance : 6 %

Osmolality (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	22	100.0	0.0	0.0	349	1.4	e

Potassium-K22



QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	11	100.0	0.0	0.0	3.6	1.9	e

Sodium-K22



QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	11	100.0	0.0	0.0	143	0.9	e

Glucose-K22



QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	11	100.0	0.0	0.0	4.4	3.4	e

Urea-K22



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	11	100.0	0.0	0.0	4.2	7.2	e*

Osmotic Gap



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	8	100.0	0.0	0.0	55.3	9.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Digoxin



QUALAB tolerance : 24 %

Digoxin (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	1.38	11.3	e*
2	Other methods	8	100.0	0.0	0.0	1.68	9.7	e*

Phenytoin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	34	6.2	e*

Phenobarbital



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	86	6.5	e*

Paracetamol



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	190.0	5.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Vancomycin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	8.7	3.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat



MQ tolerance : 24 %

Valproat (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	407.3	10.8	a

Carbamazepin



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	28.8	7.9	e*

Cystatin C



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	17	88.2	5.9	5.9	0.76	9.7	e
2	Nephelometry	5	100.0	0.0	0.0	0.74	8.1	e*

Ethanol



QUALAB tolerance : 18 %
(< 10.0: +/- 1.8 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Others	4	100.0	0.0	0.0	9.0	3.0	e
2	Abbott	8	100.0	0.0	0.0	8.4	8.3	e*
3	Roche, Cobas	24	100.0	0.0	0.0	8.3	9.5	a

Ammonia



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	100.0	0.0	0.0	56.3	9.1	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Calprotectin



MQ tolerance : 40 %
(< 50: +/- 20 µg/g)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann fCALturbo	21	90.5	0.0	9.5	238	13.7	e
2	Bühlmann Quantum Blu	5	80.0	0.0	20.0	82	26.4	a
3	Liaison	12	83.3	0.0	16.7	41	14.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101



QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	330	98.8	0.3	0.9	3.62	2.4	e
2	Afinion	451	97.7	0.7	1.6	3.58	3.6	e

Cholesterol HDL Af/b101



QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	327	92.4	0.3	7.3	0.72	6.2	e
2	Afinion	450	92.5	0.2	7.3	0.74	4.5	e

Tryglycerides Af/b101



QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	327	99.1	0.0	0.9	1.49	3.5	e
2	Afinion	452	99.4	0.2	0.4	1.50	4.6	e

Cholesterol PTS



QUALAB tolerance : 10 %

Cholesterol PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	4	75.0	25.0	0.0	3.17	7.1	e*

Cholesterol HDL PTS



QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	4	100.0	0.0	0.0	2.16	12.0	e*

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	4	75.0	0.0	25.0	1.41	4.0	e

Troponin I AFIAS



QUALAB tolerance : 24 %

Troponin I AFIAS (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	498	87.4	10.0	2.6	617.89	13.9	e

NT-proBNP AFIAS



QUALAB tolerance : 27 %

NT-proBNP AFIAS (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	384	93.5	4.2	2.3	557.2	12.2	e

Homocystein



MQ tolerance : 30 %

Homocystein (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	7	100.0	0.0	0.0	20.5	2.4	e
2	all Participants	6	100.0	0.0	0.0	17.3	3.9	e

Lipase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche	5	100.0	0.0	0.0	94.0	2.4	e
2	Siemens	6	100.0	0.0	0.0	102.5	4.4	e
3	Abbott	13	100.0	0.0	0.0	88.6	4.6	e
4	Beckman	5	100.0	0.0	0.0	90.0	1.9	e
5	Roche	27	100.0	0.0	0.0	91.6	5.2	e
6	Fuji Dri-Chem	173	98.3	0.0	1.7	79.3	4.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Fructosamine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	4	100.0	0.0	0.0	514	5.2	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Bicarbonat



MQ tolerance : 15 %

Bicarbonat (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	8	87.5	12.5	0.0	21.0	8.2	e*
2	Piccolo	4	100.0	0.0	0.0	26.5	5.2	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose CSF



QUALAB tolerance : 9 %
(< 3.30: +/- 0.30 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	1.88	2.7	e
2	Other methods	13	100.0	0.0	0.0	1.86	3.3	e

Lactate CSF



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	15	93.3	0.0	6.7	3.97	2.6	e
2	Other methods	9	88.9	0.0	11.1	4.04	1.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein CSF



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	20	100.0	0.0	0.0	0.93	2.5	e
2	Other methods	7	100.0	0.0	0.0	0.90	6.5	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine CSF



MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	7	85.7	14.3	0.0	340.00	10.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

CDT



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Immunoassay	4	100.0	0.0	0.0	1.61	7.0	e*
2	Other methods	6	100.0	0.0	0.0	1.35	14.4	a

Tacrolimus



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	16.2	5.3	e

Totalprotein E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	20	95.0	0.0	5.0	70.6	2.4	e

Albumin E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	33	100.0	0.0	0.0	62.9	5.7	e

alpha-1-Globuline



MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	2.6	9.1	e
2	capillary electropho	20	100.0	0.0	0.0	4.3	4.3	e

alpha-2-Globuline



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	33	81.8	15.2	3.0	8.6	16.3	e

beta-Globuline



MQ tolerance : 30 %

beta-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	10	100.0	0.0	0.0	8.0	8.0	e

Beta-1-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	76.9	0.0	23.1	7.3	8.9	a

Beta-2-Globulin



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	12	75.0	8.3	16.7	4.6	19.1	e*

gamma-Globuline



MQ tolerance : 30 %

gamma-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	20	100.0	0.0	0.0	12.6	11.9	a

Gamma-Globuline+P



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	17.1	15.5	a

Beta-Globuline+P



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	10	100.0	0.0	0.0	11.5	8.6	e

Folate in Erythrocytes



MQ tolerance : 40 %

Folate in Erythrocytes (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	5	80.0	20.0	0.0	580	30.4	a
2	Abbott	11	100.0	0.0	0.0	184	11.1	e
3	Roche, Cobas	26	96.2	0.0	3.8	1212	12.1	e

Gallensäure



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	7	100.0	0.0	0.0	15.2	12.3	e*
2	Roche	12	100.0	0.0	0.0	17.5	7.0	e
3	Abbott	6	100.0	0.0	0.0	14.2	5.2	e
4	Siemens	6	100.0	0.0	0.0	13.9	4.9	e

BNP



QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	5	100.0	0.0	0.0	7.0	6.6	e

Troponin I Triage



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	286	95.9	2.4	1.7	510.50	11.5	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

NT-pro BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	156	91.6	2.6	5.8	180	12.9	e

Vitamin D 25 (OH)



QUALAB tolerance : 27 %

Vitamin D 25 (OH) (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	LCMS	4	100.0	0.0	0.0	77.5	3.4	a
2	AFIAS	8	75.0	25.0	0.0	49.3	22.7	e*
3	Cobas	22	100.0	0.0	0.0	64.0	9.1	e
4	VIDAS	5	100.0	0.0	0.0	73.1	7.5	e*
5	Other methods	5	80.0	20.0	0.0	47.1	20.4	e*
6	Abbott	9	100.0	0.0	0.0	69.6	5.1	e
7	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	59.3	8.2	e*

Vitamin D 1,25-(OH)2



MQ tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	4	100.0	0.0	0.0	70.2	3.8	e

AMH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	100.0	0.0	0.0	16.6	3.9	e
2	Beckman	5	100.0	0.0	0.0	18.7	9.9	a

Inhibin B



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	220.0	28.3	a

Calcitonin



MQ tolerance : 25 %

Calcitonin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	2.1	19.0	a
2	Other methods	7	100.0	0.0	0.0	5.4	7.5	e

IGF-BP3



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	85.7	0.0	14.3	3.30	5.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Renin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	9	100.0	0.0	0.0	90.4	12.2	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Aldosteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	6	100.0	0.0	0.0	67.7	13.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti Thyreoglobulin



MQ tolerance : 25 %
(< 10: +/- 3 IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	6	100.0	0.0	0.0	10	9.2	e*
2	Roche, Cobas	13	100.0	0.0	0.0	95	5.0	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	14	92.9	7.1	0.0	42	13.5	e*
2	Abbott	5	100.0	0.0	0.0	70	3.5	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK



MQ tolerance : 25 %
(< 2.00: +/- 0.50 IU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	6	100.0	0.0	0.0	0.70	0.0	e
2	Roche, Cobas	9	100.0	0.0	0.0	0.80	12.0	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine WB



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	82	81.7	9.8	8.5	274	11.5	e

eGFR CDK-EPI WB



MQ tolerance : 30 %

eGFR CDK-EPI WB ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	4	100.0	0.0	0.0	24	12.9	e*

IL6

MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	4	100.0	0.0	0.0	217.0	4.2	e

Pankreas Elastase



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	15	93.3	0.0	6.7	129	18.4	e

Copeptin



MQ tolerance : 30 %

Copeptin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Kryptor	7	100.0	0.0	0.0	4.9	12.5	e*

Occult blood qn



MQ tolerance : 30 %

Occult blood qn (ng/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OC-Sensor	8	100.0	0.0	0.0	167	34.9	a

Amylase-Urine



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	7	100.0	0.0	0.0	183	4.7	e

Pancreatic Amylase-Urine



QUALAB tolerance : 18 %
(< 25.0: +/- 5.0 U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	4	100.0	0.0	0.0	5.8	12.0	e*

Calcium-Urine



MQ tolerance : 9 %

Calcium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	19	100.0	0.0	0.0	2.64	2.8	e
2	Abbott	11	100.0	0.0	0.0	2.55	2.8	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	11	100.0	0.0	0.0	185	1.5	e
2	Roche, Cobas	16	100.0	0.0	0.0	183	1.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose-Urine



QUALAB tolerance : 9 %

Glucose-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	27	100.0	0.0	0.0	16.6	2.2	e

Magnesium-Urine



MQ tolerance : 12 %

Magnesium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	17	100.0	0.0	0.0	3.57	3.9	e
2	AAS	5	100.0	0.0	0.0	3.70	2.6	e

Osmolality-Urine



MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	21	100.0	0.0	0.0	825	1.3	e

Phosphate-Urine



MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	29	96.6	3.4	0.0	16.3	5.1	e

Potassium-Urine



MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	39	100.0	0.0	0.0	72	2.7	e

Protein-Urine



QUALAB tolerance : 15 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	24	100.0	0.0	0.0	524.6	2.7	e
2	Dimension	4	100.0	0.0	0.0	717.0	4.9	e*
3	Abbott	16	100.0	0.0	0.0	646.6	4.6	e

Sodium-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	39	100.0	0.0	0.0	174	2.6	e

Urea-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	36	100.0	0.0	0.0	260	4.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Uric Acid-Urine



MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	1.08	3.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Specific Gravity-Urine



MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	5	100.0	0.0	0.0	1.022	0.2	e

Ethylglucuronid



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	1.20	10.2	e*

Creatinine U



QUALAB tolerance : 24 %
(< 20.0: +/- 4.8 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	92.3	0.0	7.7	27.8	3.3	e
2	Roche, Cobas	22	100.0	0.0	0.0	25.3	5.5	e
3	Siemens	4	100.0	0.0	0.0	27.0	7.3	e*
4	Aution	9	100.0	0.0	0.0	10.0	0.0	e
5	AFIAS	13	76.9	15.4	7.7	27.4	16.5	e*
6	Afinion	511	95.6	2.2	2.2	25.1	9.3	e
7	Sysmex U	15	66.7	0.0	33.3	30.0	0.0	e
8	Other methods	4	25.0	0.0	75.0	30.0	0.0	a
9	DCA2000/Vantage	162	90.7	3.1	6.2	25.6	9.4	e
10	Siemens Clinitek	25	68.0	4.0	28.0	30.0	8.0	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Creatinin Urin



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Abbott	13	100.0	0.0	0.0	3.5	4.0	e
2	Roche	28	100.0	0.0	0.0	3.7	4.5	e
3	Beckman	4	100.0	0.0	0.0	3.8	4.8	e
4	Siemens	5	100.0	0.0	0.0	3.4	10.0	e*
5	DCA2000/Vantage	160	90.6	3.1	6.3	3.9	7.2	e
6	Afinion	505	97.6	1.0	1.4	3.4	5.7	e
7	Standard chemistry	4	75.0	0.0	25.0	3.7	5.9	a
8	Sysmex U	12	83.3	0.0	16.7	4.4	0.0	e
9	Aution	9	55.6	0.0	44.4	4.4	0.0	e
10	Siemens Clinitek	22	77.3	0.0	22.7	4.4	0.2	a
11	Other methods	5	60.0	0.0	40.0	4.4	0.0	a

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CMV NAT qn



CMV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	4.85	6.5	e*

HBV NAT qn



HBV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	0.00	0.0	e*

HCV NAT qn



HCV NAT qn (Log10 IU/m)

QUALAB tolerance : +/- 0.50 Log10 IU/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	3.81	4.0	e*

HIV1 NAT qn



HIV1 NAT qn (Log10 cp/m)

QUALAB tolerance : +/- 0.50 Log10 cp/m

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	7	100.0	0.0	0.0	3.69	5.3	e*